Stephen Hoge Sells 255 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNAGet Free Report) President Stephen Hoge sold 255 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $120.96, for a total value of $30,844.80. Following the transaction, the president now directly owns 1,486,508 shares of the company’s stock, valued at $179,808,007.68. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Stephen Hoge also recently made the following trade(s):

  • On Monday, April 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $105.02, for a total value of $1,575,300.00.
  • On Thursday, February 29th, Stephen Hoge sold 2,388 shares of Moderna stock. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16.

Moderna Stock Performance

MRNA stock opened at $128.32 on Wednesday. The company has a fifty day moving average price of $108.90 and a 200 day moving average price of $96.69. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $142.79. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNAGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping the consensus estimate of ($3.59) by $0.52. The business had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company’s quarterly revenue was down 91.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.19 earnings per share. Equities research analysts anticipate that Moderna, Inc. will post -7.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Moderna

Several institutional investors and hedge funds have recently added to or reduced their stakes in MRNA. Park Avenue Securities LLC acquired a new position in Moderna during the third quarter worth $566,000. TIAA Trust National Association purchased a new stake in Moderna in the third quarter valued at approximately $453,000. Hennion & Walsh Asset Management Inc. grew its stake in shares of Moderna by 6.3% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 3,322 shares of the company’s stock valued at $343,000 after buying an additional 197 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its stake in Moderna by 9.6% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 927,757 shares of the company’s stock worth $95,828,000 after acquiring an additional 81,062 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its position in Moderna by 1.0% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 28,663 shares of the company’s stock worth $2,961,000 after purchasing an additional 279 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on MRNA shares. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Royal Bank of Canada increased their target price on Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Canaccord Genuity Group increased their price objective on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a report on Friday, May 3rd. Finally, Evercore ISI began coverage on Moderna in a research report on Tuesday. They set an “in-line” rating and a $120.00 target price on the stock. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Moderna currently has an average rating of “Hold” and a consensus price target of $126.46.

Read Our Latest Report on Moderna

Moderna Company Profile

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Featured Stories

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.